Literature DB >> 7624928

Comparison of three methods for cyclosporine area under the curve monitoring calculations.

G M Dalere1, B L Lum, G F Cooney, M Wong-Chin.   

Abstract

A method of therapeutic monitoring of cyclosporine by using area under the curve (AUC) has been previously proposed. However, different mathematical methods of calculating AUC may produce different results. We compared three methods of calculating whole blood 12-h AUC of cyclosporine A (CsA) at steady state in 16 pediatric renal allograft recipients. The linear trapezoidal method tended to significantly overestimate AUC when compared with a method combining linear and log trapezoidal methods, or the Lagrange technique combined with the logarithmic trapezoidal method, producing mean differences of 13.8 ng*h/ml [95% confidence interval (CI), 7.3-20.3] and 12.8 ng*h/ml [95% CI, 7.3-18.3], respectively. However, these differences appear to be of little clinical significance because they comprised < 1% of the calculated AUC value. The calculated AUCs by the three methods produced values with similar means and overlapping 95% CI. These data suggest that use of any of these three mathematical methods, when used to calculate CsA AUC for the determination of average steady-state concentrations and dose rate calculations, will produce similar results.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7624928     DOI: 10.1097/00007691-199506000-00015

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  6 in total

1.  Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.

Authors:  Franziska Schädeli; Hans-Peter Marti; Felix J Frey; Dominik E Uehlinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Combined cyclosporine and prednisolone therapy using cyclosporine blood concentration monitoring for adult patients with new-onset minimal change nephrotic syndrome: a single-center pilot randomized trial.

Authors:  Sayuri Shirai; Naohiko Imai; Shina Sueki; Katsuomi Matsui; Naoto Tominaga; Tsutomu Sakurada; Takashi Yasuda; Kenjiro Kimura; Yugo Shibagaki
Journal:  Clin Exp Nephrol       Date:  2017-07-11       Impact factor: 2.801

3.  Age effect on whole blood cyclosporine concentrations following oral administration in children with nephrotic syndrome.

Authors:  Katsumi Ushijima; Osamu Uemura; Takuji Yamada
Journal:  Eur J Pediatr       Date:  2011-11-26       Impact factor: 3.183

4.  Cyclosporin A in idiopathic chronic fibrosing interstitial pneumonia without idiopathic pulmonary fibrosis.

Authors:  Reoto Takei; Machiko Arita; Fumiaki Tokioka; Hiromasa Tachibana; Hironobu Tokumasu; Tadashi Ishida
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

5.  Preprandial microemulsion cyclosporine administration is effective for patients with refractory nephrotic syndrome.

Authors:  Sayuri Shirai; Takashi Yasuda; Hiroki Tsuchida; Shingo Kuboshima; Yusuke Konno; Yoshinori Shima; Takeo Sato; Shigeo Hatta; Keisou Masuhara; Kenjirou Kimura
Journal:  Clin Exp Nephrol       Date:  2008-12-05       Impact factor: 2.801

Review 6.  Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity.

Authors:  G R Matzke; R F Frye
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.